UBS Adjusts CARsgen Therapeutics' Price Target to HK$34.50 From HK$38, Keeps at Buy
UBS Adjusts CARsgen Therapeutics' Price Target to HK$34.50 From HK$38, Keeps at Buy
瑞銀將CarsGen Therapeutics的目標股價從38港元調整至34.50港元,維持買入水平
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊